Please assess the completion status of the following clinical trial:

Trial Title: Levobupivacaine to the Surgical Wound Following Cesarean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Full-term pregnant women who undergo scheduled cesarean surgery under intradural anesthesia.~* Duly informed patients who have signed the informed consent during the preanesthesia consultation, or after a period of consideration if necessary, expressing their consent to be included in the study.~* Between 18-45 years of age.~* ASA I and II.~* Sufficient intellectual ability to understand the technique as well as the equipment being used.~Exclusion Criteria:~* Failure to meet any of the above criteria.~* Presence of a major medical, cardiovascular, pulmonary, metabolic, renal or liver disorder.~* Preeclampsia and/or HELLP syndrome.~* Coagulopathy~* Profuse bleeding greater than 1000 ml or that which provokes hemodynamic instability that requires aggressive fluid therapy and/or transfusion.~* Allergy to any drug included in the protocol.~* Psychiatric or neurological pathology.~* Preexisting infection.~* Previous treatment with opioids or antidepressants or suffer from chronic pain.~* History of alcohol or drug abuse or known consumption of medications that interfere with LB metabolism.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Levobupivacaine (Type: EXPERIMENTAL): Continuous levobupivacaine subfascial infusion
- NaCl (Type: PLACEBO_COMPARATOR): Continuous NaCl subfascial infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).